Chemical Drug Development

Service List

• From targets selection, compound screening, lead optimization to PCC identification.Comprehensive druggability evaluationsCMC servicesPreclinical evaluations including studies on pharmacology, pharmacokinetics and toxicity. IND filings with China NMPA, US FDA, Europe (EMA) CTA and Australia (ARGPM) TGA.

Advanced Technologies

• SAR compound synthesisFast assembly of PROTAC molecules and PROTAC screeningFast buildings of ADC payloads and ADC screeningGreen chemistryBiaCore screening

Features

• An efficient team driven by your deadlines
  We are proud of our professional and efficient R&D team.Over 40% of our team members have either a master's degree, doctorate.On every project, we make full use of every second so to ensure overall efficiency and project punctuality.We guarantee: Fee for service (FFS) on-time delivery rate > 80%; Chemical reaction success rate > 85%; One compound delivered per full-time equivalent (FTE) each week;The number of reactions completed by each scientific researcher each week > 12.
• Advanced equipment
  Supported by high-throughput chromatography and mass spectrometry and advanced processing software, Medicilon sets high standards for our compound screening and analysis, optimization of lead compounds, analysis of chemical and physical property assessment  of compounds. Our 10,000 m2 laboratory in Shanghai Nanhui Industrial Park is equipped with a comprehensive library of instruments and is managed under a modern business model and philosophy. We guarantee the quality and efficiency of any project we undertake.
• PROTAC technology platform
  Our Medicinal Chemistry Department has established a PROTAC drug discovery platform that contains popular target protein ligands. We have also established libraries for high-affinity targeting protein small molecule (TPSM) and small molecular fragments, libraries for high-affinity ubiquitin ligase small molecule (E3SM) and small molecular fragments, and linker systems that include diversified bi-functional linkers (BF-Linker). Those compound libraries help our scientists to quickly and efficiently synthesize a large number of high-activity PROTAC bi-specific small molecules, thus greatly accelerating the process of drug R&D.

Service Cases

FAQs

• What is Ideal Synthetic Route?

  Economic and reasonable
  • Simple synthesis route with few steps
  • FDA: The proposed starting material should react multiple steps apart from the final intermediate of the API
  • The raw materials are easy to obtain and stable.
  • Intermediates are easily separated and stable.
  • It is easy to operate and reaches the medicinal standard after separation and purification.
  • High yield, low cost and maximum economic benefit

  Green, Safe
  • No high-risk reaction
  • Minimize the generation of Genetic Impurities.
  • Less demanding production equipment requirements
  • Generate less waste, which is easy to treat

Relevant laboratories

• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
•